Medical guideline

首页肿瘤学指南检索结果

检索结果

按发表年份

共搜索到7条与Ontario Health (Cancer Care Ontario)有关的结果

Therapy for Stage IV Non-Small-Cell Lung Cancer with Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

2021年发布于 Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39卷第9期 所属人体系统：呼吸 | 肺癌

American Society of Clinical Oncology Ontario Health (Cancer Care Ontario)

Stage IV Non-small-cell Lung Cancer Therapy Driver Alterations Guideline
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
Therapy for Stage IV Non-Small-Cell Lung Cancer without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

2020年发布于 Journal of Clinical Oncology 39卷第9期 所属人体系统：呼吸 | 肺癌

American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario)

Stage IV Non-small-cell Lung Cancer Driver Alterations Therapy Guideline
指南简介 原文链接
Locoregional Management of In-transit Metastasis in Melanoma: an Ontario Health (Cancer Care Ontario) Clinical Practice Guideline

2020年发布于 Curr Oncol 27卷第3期 所属人体系统：其他 | 黑色素瘤

The Program in Evidence-Based Care (pebc) of Ontario Health (Cancer Care Ontario) and the Melanoma Disease Site Group.

In-transit Metastasis Itm Melanoma Practice Guidelines.
指南简介 原文链接
Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Cutaneous Or Mucosal Melanoma: an Ontario Health (cancer Care Ontario) Clinical Practice Guideline

2020年发布于 Current Oncology 27卷第1期 所属人体系统：其他 | 黑色素瘤

Evidence-Based Care (pebc) at Ontario Health (Cancer Care Ontario) Melanoma Disease Site Group

Melanoma Adjuvant Therapy Immune Checkpoint Inhibitors Interferon Practice Guidelines Targeted Therapy.
指南简介 原文链接

人体系统

共搜索到7条 与Ontario Health (Cancer Care Ontario)有关的结果

2021年 发布于 Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39卷 第9期 所属人体系统： 呼吸 | 肺癌

American Society of Clinical Oncology Ontario Health (Cancer Care Ontario)

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

2020年 发布于 Journal of Clinical Oncology 39卷 第9期 所属人体系统： 呼吸 | 肺癌

American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario)

2020年 发布于 Curr Oncol 27卷 第3期 所属人体系统： 其他 | 黑色素瘤

The Program in Evidence-Based Care (pebc) of Ontario Health (Cancer Care Ontario) and the Melanoma Disease Site Group.

2020年 发布于 Current Oncology 27卷 第1期 所属人体系统： 其他 | 黑色素瘤

Evidence-Based Care (pebc) at Ontario Health (Cancer Care Ontario) Melanoma Disease Site Group

共搜索到7条与Ontario Health (Cancer Care Ontario)有关的结果

2021年发布于 Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39卷第9期 所属人体系统：呼吸 | 肺癌

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

2020年发布于 Journal of Clinical Oncology 39卷第9期 所属人体系统：呼吸 | 肺癌

2020年发布于 Curr Oncol 27卷第3期 所属人体系统：其他 | 黑色素瘤

2020年发布于 Current Oncology 27卷第1期 所属人体系统：其他 | 黑色素瘤